192 related articles for article (PubMed ID: 11295624)
1. Chemoprevention for prostatic carcinoma: The role of flutamide in patients with prostatic intraepithelial neoplasia.
Alberts SR; Blute ML
Urology; 2001 Apr; 57(4 Suppl 1):188-90. PubMed ID: 11295624
[TBL] [Abstract][Full Text] [Related]
2. Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trial.
Alberts SR; Novotny PJ; Sloan JA; Danella J; Bostwick DG; Sebo TJ; Blute ML; Fitch TR; Levitt R; Lieberman R; Loprinzi CL
Am J Ther; 2006; 13(4):291-7. PubMed ID: 16858161
[TBL] [Abstract][Full Text] [Related]
3. Influence of irradiation and androgen ablation on prostatic intraepithelial neoplasia.
Wheeler TM
Eur Urol; 1996; 30(2):261-4. PubMed ID: 8875209
[TBL] [Abstract][Full Text] [Related]
4. Prostatic intraepithelial neoplasia and prostate cancer.
Montironi R; Santinelli A; Mazzucchelli R
Panminerva Med; 2002 Sep; 44(3):213-20. PubMed ID: 12094135
[TBL] [Abstract][Full Text] [Related]
5. Chemoprevention for prostatic intraepithelial neoplasia.
Nelson PS; Gleason TP; Brawer MK
Eur Urol; 1996; 30(2):269-78. PubMed ID: 8875211
[TBL] [Abstract][Full Text] [Related]
6. Flutamide reduced prostate cancer development and prostate stem cell antigen mRNA expression in high grade prostatic intraepithelial neoplasia.
Zhigang Z; Wenlu S
Int J Cancer; 2008 Feb; 122(4):864-70. PubMed ID: 17957793
[TBL] [Abstract][Full Text] [Related]
7. Chemoprevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia (HGPIN): a systematic review and adjusted indirect treatment comparison.
Cui K; Li X; Du Y; Tang X; Arai S; Geng Y; Xi Y; Xu H; Zhou Y; Ma W; Zhang T
Oncotarget; 2017 May; 8(22):36674-36684. PubMed ID: 28415774
[TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development.
Lieberman R
Urology; 2001 Aug; 58(2 Suppl 1):83-90. PubMed ID: 11502457
[TBL] [Abstract][Full Text] [Related]
9. Histological markers of risk and the role of high-grade prostatic intraepithelial neoplasia.
Sakr WA; Partin AW
Urology; 2001 Apr; 57(4 Suppl 1):115-20. PubMed ID: 11295607
[TBL] [Abstract][Full Text] [Related]
10. Persistence of high-grade prostatic intra-epithelial neoplasia under combined androgen blockade therapy.
van der Kwast TH; Labrie F; Tetu B
Hum Pathol; 1999 Dec; 30(12):1503-7. PubMed ID: 10667430
[TBL] [Abstract][Full Text] [Related]
11. Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model.
Raghow S; Kuliyev E; Steakley M; Greenberg N; Steiner MS
Cancer Res; 2000 Aug; 60(15):4093-7. PubMed ID: 10945615
[TBL] [Abstract][Full Text] [Related]
12. Suppressive effects of antiandrogens, finasteride and flutamide on development of prostatic lesions in a transgenic rat model.
Cho YM; Takahashi S; Asamoto M; Suzuki S; Tang M; Shirai T
Prostate Cancer Prostatic Dis; 2007; 10(4):378-83. PubMed ID: 17457304
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene.
Taneja SS; Morton R; Barnette G; Sieber P; Hancock ML; Steiner M
J Clin Oncol; 2013 Feb; 31(5):523-9. PubMed ID: 23295793
[TBL] [Abstract][Full Text] [Related]
14. Effect of androgen deprivation therapy on prostatic intraepithelial neoplasia.
Bostwick DG; Qian J
Urology; 2001 Aug; 58(2 Suppl 1):91-3. PubMed ID: 11502458
[TBL] [Abstract][Full Text] [Related]
15. Is low-grade prostatic intraepithelial neoplasia a risk factor for cancer?
Goeman L; Joniau S; Ponette D; Van der Aa F; Roskams T; Oyen R; Van Poppel H
Prostate Cancer Prostatic Dis; 2003; 6(4):305-10. PubMed ID: 14663472
[TBL] [Abstract][Full Text] [Related]
16. Extent and zonal distribution of prostatic intraepithelial neoplasia in patients with prostatic carcinoma in Japan: analysis of whole-mounted prostatectomy specimens.
Shin M; Takayama H; Nonomura N; Wakatsuki A; Okuyama A; Aozasa K
Prostate; 2000 Feb; 42(2):81-7. PubMed ID: 10617864
[TBL] [Abstract][Full Text] [Related]
17. Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917.
Marshall JR; Tangen CM; Sakr WA; Wood DP; Berry DL; Klein EA; Lippman SM; Parnes HL; Alberts DS; Jarrard DF; Lee WR; Gaziano JM; Crawford ED; Ely B; Ray M; Davis W; Minasian LM; Thompson IM
Cancer Prev Res (Phila); 2011 Nov; 4(11):1761-9. PubMed ID: 21896650
[TBL] [Abstract][Full Text] [Related]
18. Apoptotic regulators in prostatic intraepithelial neoplasia (PIN): value in prostate cancer detection and prevention.
Zeng L; Kyprianou N
Prostate Cancer Prostatic Dis; 2005; 8(1):7-13. PubMed ID: 15477876
[TBL] [Abstract][Full Text] [Related]
19. Precancerous lesions and conditions of the prostate: from morphological and biological characterization to chemoprevention.
Montironi R; Mazzucchelli R; Scarpelli M
Ann N Y Acad Sci; 2002 Jun; 963():169-84. PubMed ID: 12095942
[TBL] [Abstract][Full Text] [Related]
20. Randomized, controlled chemoprevention trials in populations at very high risk for prostate cancer: Elevated prostate-specific antigen and high-grade prostatic intraepithelial neoplasia.
Clark LC; Marshall JR
Urology; 2001 Apr; 57(4 Suppl 1):185-7. PubMed ID: 11295623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
